Cargando…

Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches

SIMPLE SUMMARY: Estrogen is known to drive the growth of estrogen-receptor-positive breast cancers, the most common breast cancer subtype. Drugs that target the estrogen receptor by blocking estrogen signaling are the mainstay of treatment. These drugs include tamoxifen, aromatase inhibitors and sel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shete, Nivida, Calabrese, Jordan, Tonetti, Debra A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377916/ https://www.ncbi.nlm.nih.gov/pubmed/37509308 http://dx.doi.org/10.3390/cancers15143647

Ejemplares similares

Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer
por: Abderrahman, Balkees, et al.
Publicado: (2020)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
por: Jeffreys, Sarah A., et al.
Publicado: (2020)

Role of estrogen receptor coregulators in endocrine resistant breast cancer
por: Altwegg, Kristin A., et al.
Publicado: (2021)

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
por: Wang, Yubo, et al.
Publicado: (2023)

PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer
por: Fan, Ping, et al.
Publicado: (2022)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Exendin-4 — A potential therapeutic for type 2 diabetes-linked cervical cancer?
por: Mishra, Nivida, et al.
Publicado: (2021)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
por: Weigel, Marion T, et al.
Publicado: (2012)

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Nabieva, Naiba, et al.
Publicado: (2021)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011)

Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells
por: Horie, Kuniko, et al.
Publicado: (2022)

Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells
por: Pal, Purab, et al.
Publicado: (2022)

New insights into acquired endocrine resistance of breast cancer
por: Fan, Ping, et al.
Publicado: (2019)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
por: Strillacci, Antonio, et al.
Publicado: (2022)

The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
por: Rodriguez, David, et al.
Publicado: (2019)

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer
por: Traphagen, Nicole A., et al.
Publicado: (2021)

Prevention of breast cancer by recapitulation of pregnancy hormone levels
por: Tonetti, Debra A
Publicado: (2004)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer
por: Castillo-Castrejon, Marisol, et al.
Publicado: (2023)

microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
por: Howard, Erin W., et al.
Publicado: (2018)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Revisiting Standard and Novel Therapeutic Approaches in Halitosis: A Review
por: Izidoro, Catarina, et al.
Publicado: (2022)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
por: Achinger-Kawecka, Joanna, et al.
Publicado: (2020)

ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
por: Nath, Aritro, et al.
Publicado: (2022)

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2023)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
por: Mao, XiaoDan, et al.
Publicado: (2019)

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
por: Schiff, Rachel, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_cdq14qs9qc966hns72lr968q8d